Get the Stockscreener App
183.63
2.68%
-5.06
After Hours:
183.63
Jazz Pharmaceuticals Plc stock is traded at $183.63, with a volume of 802.40K.
It is down -2.68% in the last 24 hours and up +12.55% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$188.69
Open:
$187.01
24h Volume:
802.40K
Relative Volume:
0.78
Market Cap:
$11.30B
Revenue:
$4.27B
Net Income/Loss:
$-356.15M
P/E Ratio:
-30.76
EPS:
-5.9702
Net Cash Flow:
$1.19B
1W Performance:
-2.83%
1M Performance:
+12.55%
6M Performance:
+41.80%
1Y Performance:
+30.95%
1-Day Range:
$182.95
$189.02
1-Week Range:
$182.95
$192.70
52-Week Range:
$95.49
$198.00
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
183.63 | 11.62B | 4.27B | -356.15M | 1.19B | -5.9702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Downgrade | UBS | Buy → Neutral |
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Deutsche Bank Adjusts Jazz Pharmaceuticals Price Target to $226 From $225, Maintains Buy Rating - marketscreener.com
GW&K Investment Management LLC Sells 17,849 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Mixed Recent Returns And A 5.7% Undervaluation Estimate - simplywall.st
Insider Sell: Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals PLC (JAZZ) - GuruFocus
JAZZ SEC FilingsJazz Pharmaceuticals Plc 10-K, 10-Q, 8-K Forms - Stock Titan
https://www.msn.com/en-us/money/companies/jazz-pharmaceuticals-plc-jazz-reports-1-2-billion-q4-revenue-beats-1-17b-estimate/ar-AA1Xsvc3?ocid=finance-verthp-feeds - MSN
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) Reports $1.2 Billion Q4 Revenue, Beats $1.17B Estimate - Finviz
Jazz Pharmaceuticals (NASDAQ: JAZZ) lists option-derived shares for sale via Merrill Lynch - Stock Titan
Is Jazz Pharmaceuticals (JAZZ) Still Attractive After A 36% One Year Share Price Jump - simplywall.st
JAZZ: Record growth, pipeline advances, and rare disease focus drive strong 2026 outlook - TradingView
JAZZ: Record growth, pipeline advances, and new filings drive strong outlook for 2026 - TradingView
JAZZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 3,415 Shares - MarketBeat
Jazz Pharmaceuticals Director Sells 3,415 Shares - TradingView
Jazz Pharmaceuticals (NASDAQ:JAZZ) EVP Neena Patil Sells 55,600 Shares - MarketBeat
Jazz Pharmaceuticals (JAZZ) director sells 3,415 shares after option exercise - Stock Titan
Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Patricia Carr Sells 1,117 Shares - MarketBeat
Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) SVP Sells 5,343 Shares of Stock - MarketBeat
Patricia Carr Sells 1,253 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock - MarketBeat
Jazz Pharmaceuticals (JAZZ) CFO granted 11,857 restricted stock units - Stock Titan
Jazz Pharmaceuticals (JAZZ) EVP awarded 9,782 restricted stock units in Form 4 - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) grants 14,822 RSUs to R&D leader - Stock Titan
Jazz Pharmaceuticals (JAZZ) SVP reports share award and open-market sales - Stock Titan
Jazz Pharmaceuticals (JAZZ) CEO receives 44,465 restricted stock units - Stock Titan
Jazz Pharmaceuticals (JAZZ) director receives 1,527-share restricted stock unit grant - Stock Titan
Jazz Pharmaceuticals Insider Sold Shares Worth $1,039,134, According to a Recent SEC Filing - marketscreener.com
Jazz Pharmaceuticals (NASDAQ: JAZZ) EVP Patil sells 55,600 shares - Stock Titan
Jazz Pharmaceuticals (JAZZ) SVP reports RSU grant and tax-driven share sale - Stock Titan
Jazz Pharmaceuticals Reports Record 2025 Revenue, Driven by Xywav Growth - Sleep Review
Jazz Pharmaceuticals (JAZZ) Stock Analysis: Unveiling A 17% Upside Potential For Investors - DirectorsTalk Interviews
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing - Yahoo Finance
Is Jazz Pharmaceuticals (JAZZ) One of the Best Cheap Biotech Stocks to Buy Now? - Insider Monkey
Jazz Pharmaceuticals (JAZZ) Is Up 10.4% After Record Q4 Revenue And New Oncology Data Release - simplywall.st
Jazz Pharmaceuticals’ Record Revenue And Cancer Data Raise Durability Question - Yahoo Finance
JAZZ Should I Buy - Intellectia AI
11 Best Pot Stocks to Buy According to Hedge Funds - Insider Monkey
Patricia Carr reports JAZZ (NASDAQ: JAZZ) sales of 1,253 and 4,660 shares - Stock Titan
[144] Jazz Pharmaceuticals plc SEC Filing - Stock Titan
This Jazz Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Benzinga
JAZZ Receives New Overweight Rating as Barclays Initiates Coverage | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Stock Surges 13% on Oncology Breakthrough: Here’s Where the Stock Could Go in 2026 - TIKR.com
Jazz Pharmaceuticals' CBD Drug Hits $1B: Time to Buy the Stock? - TradingView
Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns Overweight Rating from Analysts at Barclays - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) Jumps Nearly 30% on Strong Q3 and Cancer Drug Trial Progress - Insider Monkey
Jazz Pharmaceuticals (JAZZ) Quarterly Profit Of US$203 Million Tests Trailing Loss Narrative - simplywall.st
Jazz Pharmaceuticals (NASDAQ: JAZZ) Form 144: 10,116 restricted shares; insider sold 2,238 - Stock Titan
Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise’s Outlook (NASDAQ:JAZZ) - Seeking Alpha
Fox Run Management L.L.C. Invests $1.37 Million in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Citigroup Inc. - MarketBeat
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):